Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25
Benzinga Newsdesk 16 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $27 to $25.
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $27 to $25.